Document Detail

The electrophysiologic basis for the use of amiodarone for treatment of cardiac arrhythmias.
MedLine Citation:
PMID:  6192414     Owner:  NLM     Status:  MEDLINE    
The electrophysiologic basis for the use of amiodarone in the treatment of cardiac arrhythmias is outlined, with reference to studies in isolated cardiac tissues, whole animal, and human studies. Amiodarone appears to have the distinctive property of directly prolonging action potential duration (and hence refractory periods) in nearly all cardiac tissues. Independent of its effects on refractory periods, conduction may also be impaired in the His-Purkinje system, possibly due to depression of phase 0 of the action potential. Sinus node and atrial automaticity, as well as that arising from diseased Purkinje fibers, may be depressed. Normal ventricular escape pacemakers appear relatively unaffected, however. A nonspecific anti-adrenergic action may contribute to its observed effects. These electrophysiological effects are more obvious and predictable after several weeks of oral treatment than after intravenous administration, suggesting a time-dependent mechanism of action. The drug appears well suited to the prevention of enhanced automaticity in the ventricle and re-entry throughout the heart, and its frequent clinical success in a broad spectrum of cardiac arrhythmias attests to this. Unwanted side effects include sinus node depression, His-Purkinje conduction delay or block, and ventricular arrhythmias enhanced by QT prolongation. However, the frequency of clinically significant examples of unwanted arrhythmic effects appears to be acceptably low.
A W Hamer; W J Mandel; C A Zaher; H S Karagueuzin; T Peter
Related Documents :
11263614 - Patients at lower risk of arrhythmia recurrence: a subgroup in whom implantable defibri...
1554274 - Cardiac arrhythmias and myocardial ischemia after thoracotomy for lung cancer.
22855554 - Myocardial perfusion reserve assessed by t2-prepared steady-state free-precession blood...
8627544 - Differential efficacy of the class iii agent mk-499 against programmed stimulation-indu...
6640854 - Action of glucagon on canine left ventricular performance and coronary hemodynamics.
15702674 - Coronary artery changes in patients with kawasaki disease.
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pacing and clinical electrophysiology : PACE     Volume:  6     ISSN:  0147-8389     ISO Abbreviation:  Pacing Clin Electrophysiol     Publication Date:  1983 Jul 
Date Detail:
Created Date:  1983-09-23     Completed Date:  1983-09-23     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7803944     Medline TA:  Pacing Clin Electrophysiol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  784-94     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Action Potentials / drug effects
Amiodarone / administration & dosage,  adverse effects,  therapeutic use*
Arrhythmias, Cardiac / drug therapy*
Benzofurans / therapeutic use*
Sinoatrial Node / drug effects
Reg. No./Substance:
0/Benzofurans; 1951-25-3/Amiodarone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Use of the contralateral subclavian vein for placement of atrial electrodes in chronically VVI paced...
Next Document:  Atrial premature beats with variable return cycle lengths--a clue to sinus node re-entry?